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Abstract: Alzheimer’s and Parkinson’s diseases are the most common age-related and predominantly
idiopathic neurodegenerative disorders of unknown pathogenesis. Although these diseases differ in
their clinical and neuropathological features, they also share some common aetiologies, such as protein
aggregation, mitochondrial dysfunction, oxidative stress, and neuroinflammation. Epidemiological,
in vitro and in vivo evidences suggest an inverse correlation between wine consumption and the
incidence of neurodegenerative disorders. Wine benefits are, in large part, attributable to the intake
of specific polyphenols, which mediate cell function under both normal and pathological conditions.
In this review, we aim to provide an overview of the role that wine polyphenols play in delaying
neurodegenerative disorders. We discuss animal and in vitro studies in support of these actions and
we consider how their biological mechanisms at the cellular level may underpin their physiological
effects. Together, these data indicate that polyphenols present in wine may hold neuroprotective
potential in delaying the onset of neurodegenerative disorders.
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1. Introduction
Given the current ageing population demographics, the prevalence of dementia worldwide will
approximately double every 20 years, increasing to 115 million by 2050 [1]. As people age, their
cognitive function is threatened by the normal ageing process, as well as increasing risk for a range
of neurodegenerative conditions, most notably Alzheimer’s Disease (AD) and Parkinson’s disease
(PD) [2]. The precise cause of the neuronal degeneration underlying these disorders remains however
elusive, although it is thought that several cellular and molecular events are involved in its progression,
including oxidative stress increase, mitochondria function impairment, neuronal apoptosis activation,
aggregated proteins deposition and excitotoxicity [2]. Existing drug treatments for neurodegenerative
conditions rarely curtail the underlying disease processes, and consequently there is an urgent need to
develop alternative strategies to directly prevent, slow, and even stop neurodegeneration. Lifestyle
strategies, such as nutritional interventions, have potential to be a safe, cheap, and effective alternative
to protect against age-related cognitive decline and neurodegeneration, resulting in significant personal
and societal benefits [3].
Although the long-term high consumption of alcoholic drinks has been associated with an
increased prevalence of cancer, cardiovascular diseases, cirrhosis, dementia and depression [4],
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a low-moderate wine intake may reduce cognitive impairment [5–7], cardiovascular diseases [8–10]
and may also decrease certain types of cancer [11,12] and/or diabetes [13,14]. In addition, data from
the Personnes Agées Quid [6] study demonstrated that people drinking three to four glasses of wine
per day had an 80% decreased incidence of dementia and AD three years later, compared to those who
drank less or did not drink at all [7]. Wine polyphenols have been reported as potential preventive
agents due to their chemical and biological properties. These compounds derive mainly from the
grape seeds and skin and may be present at relatively high concentrations in wine, especially as
flavonoids (flavan-3-ols, anthocyanins) and other polyphenols (resveratrol, gallic acid or cinnamates).
Red wine is known to contain 10 times more phenolic compounds than white wine, most of which
come from the extraction derived from the skin and seeds during the fermentation process. Wine
compounds proportion, however, depends on terroir, i.e., on grape cultivar type, soil and climate
features in which grapes grow, and human activity [15,16] (see Figure 1). Polyphenols have been
ascribed with anti-inflammatory properties and are able to modulate signaling pathways that regulate
neuronal survival [17]. As such, there is a great interest in the potential of regular and moderate wine
consumption to delay the onset of neurological disorders, such as AD and PD [18].
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Figure 1. Red and white wine phenolic composition. Adapted from Waterhouse A.L. [16].
In this review, we summarize the most recent supporting mechanisms of AD and PD
pathogenesis and progression. For both disorders, we also summarise the neuroprotective abilities
of the wine compounds in correlation to the pathophysiological mechanisms involved in each
neurodegenerative disease.
2. Alzheimer Disease (AD)
Alzheimer’s disease is the most common cause of dementia in older adults. In this pathology the
damage initially appears to take place in the hippocampus, important for memory formation. As more
neurons die, additional parts of the brain, including the cerebral cortex, are affected and begin to
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shrink. Such changes progressively lead to a loss of mental, behavioral and functional abilities and
a decrease in the capacity of learning new things, carry out multistep tasks such as getting dressed,
or cope with new situations. Age is by far the main risk factor, although genetic, environmental, and
lifestyle factors may also contribute to the disease process. To date, the most prevalent hypothesis
for the pathogenesis of AD is the amyloid cascade theory where, insoluble forms of amyloid-β (Aβ)
plaques accumulate in extracellular spaces and in blood vessels walls. The process begins in neurons
with the cleavage of the amyloid precursor protein (APP), through the activity of the β-secretase
(BACE 1) and then followed by the γ-secretase. In the non-pathological pathway (non-amyloidogenic)
the γ-secretase precedes by the α-secretase activity. Amyloidogenic cleavage results in production of
peptides mainly of 40 and 42 amino acids, known as Aβ40 and Aβ42, respectively [19]. These peptides
can be converted into diffusible and soluble oligomers (Aβo) (Figure 2). The neurotoxicity of Aβo is
further exacerbated by their capacity to negatively affect long-term potentiation, therefore producing
severe damages to synaptic plasticity resulting on impaired memory and learning. When Aβo are not
removed by the astrocytic low-density lipoprotein receptor-related protein 1 (LRP 1), their aggregation
occurs to form fibrillary structures that accumulate into Aβ plaques. The latter can be cleared from the
brain through different pathways [19], including either the intervention of macrophages and microglia
cells or involving astrocytes, through endoproteases such as insulin-degrading enzyme, neprilysin
and matrix metalloproteinase [20].
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Figure 2. Diagrammatic representation of pathogenic mechanisms involved in Alzheimer’s disease.
Aβ, amyloid beta; Aβo, amyloid beta oligomers; APP, amyloid precursor protein; IL-1β, interleukin 1
beta; IFN-γ, interferon gamma; LPR1, low-density lipoprotein receptor-related protein 1; ROS, reactive
oxygen species; TNF-α, tumor necrosis factor alpha.
Some conformational Aβo, that dissociate from both Aβ fibrils and plaques, may not be removed
and are toxic to adjacent synapses and mitochondria. Furthermore, Aβo induce activation of microglia
and astrocytes. With microglial activation, proinflammatory cytokines, including interleukin 1 beta
(IL-1β), tumor necrosis factor alpha (TNF-α), and interferon gamma (IFN-γ) are produced. These
molecules accumulate nearby astrocyte-neuron stimulating the production of more Aβo and Aβ
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peptides [20]. Moreover, those Aβo induce intraneuronal accumulation of paired helical filaments
hyperphosphorylated tau protein abnormalities (neurofibrillary tangles, NFTs) in the brain. The exact
biochemical mechanisms of tau aggregation remain however currently unknown. Damaged neurons
are the ones with Tau-positive NFTs, which extend to the dendrites, and can be released and taken up
by healthy neurons, triggering tau damage in the uptaking cell (Figure 2) [21].
Brain metabolism depends exclusively on glucose utilisation and its metabolism in the
mitochondria, via the Krebs cycle and the electron transport chain (ETC). It is estimated that about 2% of
the O2 used by the mitochondria is converted into superoxide radical (O2 −), with this figure increasing
in damaged or aged mitochondria [22]. Brain has also high amount of polyunsaturated fatty acids,
which in the presence of redox-active metals, such as copper (Cu) and iron (Fe), are very susceptible
to lipid peroxidation. When the scavenging system of the brain is not able to remove the excess of
reactive oxygen species (ROS) produced then oxidative stress (OS) appears. ROS accumulate in brain
tissues and cells and interact with lipids, proteins, carbohydrates and nucleic acids leading to cellular
oxidative damage (Figure 3). As a result of cellular and molecular deterioration, inflammation can
occur by the activation of the immune system [23]. In addition, ROS induced-defects in mitochondrial
energy metabolism is linked to the disruption in calcium (Ca2+) metabolism. The mitochondrial
Ca2+ sequestering is very important to maintain neurons functionality. In neurogenerative diseases,
the hyperactivation of N-methyl-D-aspartate-receptors (NMDA-type receptors) increases the Ca2+
concentration, inducing mitochondrial transition pore to open. Subsequently, pro-apoptotic proteins,
such as cytochrome c and the apoptosis inducing factor (AIF), can be released to the cytoplasm therefore
activating the apoptotic cascade and neuronal death. Furthermore, the decrease in nuclear factor
(erythroid-derived 2)-like 2 (Nrf2) expression observed in neurodegenerative diseases, supports this
theory, since Nrf2 protects neurons from the increase in intracellular Ca2+, and other toxic insults such
as OS and mitochondrial dysfunction. On the other hand, the NMDA-type receptors hyperactivation
also results in glutamate-induced excitotoxicity that can lead to neuronal necrosis [24]. Finally, OS
generated through Aβs can also activate stress kinases such as c-Jun N-terminal kinases (JNK), [25].
The high-affinity of Aβs for copper (Cu) and zinc (Zn) may also explain the formation of an oxidative
microenvironment. Indeed, at low pH Cu may induce Aβ aggregation and Aβs and APPs can reduce
Cu2+ to Cu+, in a reaction that produces hydrogen peroxide (H2O2) [26]. Oligodendrocytes have low
amount of glutathione (GSH) and high concentration of iron (Fe), therefore, they have reduced capacity
to scavenge ROS, being also very susceptible to OS [27].Beverages 2018, 4, x FOR PEER REVIEW    5  of  23 
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2.1. Targeting Aβ Protein
2.1.1. Modulation of Secretase Enzymes
α-Secretase
Cleavage of APP first occurs through the activation of α-secretase or BACE 1. In the first
case, it facilitates proteolysis of APP in a non-amyloidogenic pathway and prevents Aβ formation.
α-Secretase activation, therefore, is a distinct and a potential therapeutic approach to decrease Aβ
generation [28]. Proteases with proposed α-secretase function belong to the ADAM (“a disintegrin
and metalloproteinase domain”) family of proteins that include ADAM9, ADAM10 and ADAM17 [29].
All compounds considered for AD must cross the blood–brain–barrier and the plasma membrane [30].
The molecular weight of resveratrol is 228 Da, and therefore has emerged as a potential candidate
since its secondary metabolites have lower molecular weight and higher lipophilicity [31]. A diet
enriched with resveratrol (1g/Kg) was reported to activate α-secretase by increasing ADAM10
development expression through sirtuin 1 (SIRT1) modulation in SAMP8 mice (senescence-accelerated
mice-prone) [32] and in triple transgenic AD mouse model (3xTg-AD) (Figure 4) [33]. α-Secretase
activity was also elevated in the brain of mice treated with 6% Cabernet Sauvignon compared to
ethanol-treated control Tg2576 mice (model AD-type Aβ neuropathology) or in primary neurons
obtained from those mice (Figure 4) [34]. Similar results were also observed in SH-SY5Y cells stably
overexpressing the Swedish (APPSwe) mutation when treated with 25–100 nM quercetin [35] or in
primary cortical neurons treated with 1–10 µM myricetin (Figure 4) [36] In addition to flavonoids,
hydroxycinnamate compounds such as caffeic acid (25 µM) and/or their derivatives (e.g., caffeic
acid phenethyl ester) (30 µM) have been reported to activate α-secretase (ADAM-10) in acrolein
treated mouse hippocampal HT22 cells, (Figure 4) [37]. However, 3-months treatment with ferulic
acid (30 mg/kg) failed to reduce such activity in 12-month old presenilin-amyloid β-protein precursor
(PSAPP) transgenic mice [38].Beverages 2018, 4, x FOR PEER REVIEW    6  of  23 
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β-Secretase
AD mechanisms analysis (Figure 2) clearly highlights the therapeutic importance of blocking
BACE 1 activity to decrease Aβ accumulation. Five resveratrol oligomers isolated from the stembark
extract of Vitis vinifera [39] along with eleven resveratrol oligomers, isolated from the seed extract of
Paeonia lactiflora (Paeoniaceae) [40], were reported to inhibit baculovirus-expressed BACE 1 activity
in a dose dependent manner. Such activity was recently confirmed in a homogeneous time-resolved
fluorescence (TRF) assay [41], showing an inhibitory activity with an IC50 of 28 mM. Similarly, gnetin
C, a resveratrol dimer (5–100 µM), was reported to suppress BACE 1 expression in SH-SY5Y cells,
to reduce Aβ42 production and to ameliorate Aβ42-lowered cell viability [42]. Similarly, miyabenol C,
a resveratrol trimer (5–20 µM), inhibited BACE1 and reduced Aβ generation in vitro (SH-SY5Y cells
and mouse neuroblastoma N2a naive cells, N2aWT) [43]. In vitro studies also suggest that flavonoids
may also inhibit BACE 1 activity. For example, the flavanol (−)-epicatechin (100 nM) [44], the flavanols
myricetin [36,45–47], quercetin [45,48] and kaempherol (20 µM) [45], all directly inhibited BACE 1
enzymatic activity in a concentration dependent manner (Figure 4). Amin et al. [49], used SH-SY5Y cell
lines treated with Aβ1–42, to estimate the biological activity and neuroprotective effect of anthocyanin
loaded nanoparticles (An-NPs). The authors suggest that An-NPs are more active and potent than
anthocyanin alone as it decreases the level of basic proteins associated with AD such as APP and BACE
1. The inhibitory effect on Aβ-induced activation of BACE 1 was also demonstrated for anthocyanins
(malvidin and oenin; 50 µM) in an in vitro study with Neuro2a cell line (Figure 4) [50].
A reduced number of in vivo assays has been carried out with flavonoids to explore their potential
as BACE 1 inhibitors. The increase of mice neuronal resistance to age related disease effect of quercetin
is explained by its BACE 1 inhibitory effect, suggesting negative regulation of APP amyloidogenesis
in old mouse brain (Figure 4) [51]. In a different study, however, quercetin supplementation had no
effect on BACE 1 mRNA expression [52]. The experimental design of these studies was very different
and may explain the different outcomes. In the former, 16-month-old male C57BL6 strain mice were
fed with high-cholesterol diet supplemented with quercetin. In the latter, female C57BL6 mice were
fed quercetin-enriched diets (2 mg/g diet) for 6 weeks. Age, gender and diet regimen may explain,
at least partially, the differences obtained. More studies are needed to clarify whether BACE 1 can be a
molecular target for quercetin (Figure 4).
In addition to flavonoids, some studies have been carried out with both stilbenes and
hydroxycinnamates. For example, SAMP8 mice fed with a diet supplemented with 1 g/Kg of
trans-resveratrol, from 2 until 9 months of age, showed no alterations in the pro-amyloidogenic
BACE 1 enzyme quantified by Western Blot [32], although a decrease in BACE 1 protein expression
was observed in the hippocampus of those mice when subjected to a combined intervention of
resveratrol (0.03%) and vitamin D (500 IU) [53]. In a recent study, wild type littermates (NoTg)
and AD transgenic (3xTg-AD) experimental groups were fed a diet supplemented with 100 mg/kg
of trans-resveratrol from 2 months of age for 10 months. Resveratrol treatment protected against
memory loss and brain pathology in 3xTg-AD mice and induced cognitive enhancement in healthy
wild type mice, an observation that might be related to the modulation of BACE1 [33]. Furthermore,
the hydroxycinnamic acid, caffeic acid conjugated to chito-oligosaccharides has the potential to be
used as BACE 1 inhibitors to reduce the risk of AD [54]. A combination of caffeic acid/caffeic acid
phenethyl ester can also restore acrolein-induced BACE 1 changes in HT22 mouse hippocampal
cells [37]. However, ferulic acid (30 mg/kg) had no effect on BACE 1 activity when one-year-old mice
with established β-amyloid plaques received daily doses of this non-flavonoid compound [38]. These
results disagree with previous data obtained by the same research group, where the administration
of the equal amount of ferulic acid inhibited amyloidogenic APP metabolism by reducing BACE 1
expression and β-secretase activity in PSAPP mice [55]. The discrepancy between results could be
related with the differences in mice age and treatment duration, which were higher in the latter study.
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γ-Secretase
Modulation of γ-secretase can also be a preventive/therapeutic strategy. Resveratrol (0–20 µM),
oxy-resveratrol (0–80 µM), and piceatannol (0–20 µM) all decreased γ-secretase processing activity
at higher doses in Neuro2a cells [56]. Resveratrol (60 µM) also inhibited γ-secretase activity in
autophagy-deteriorated cells [57]. However, Marambaud et al. (2005) using HEK293 cells stably
transfected with human APP695 cell line concluded that resveratrol (40 µM) does not inhibit Aβ
production, partly because it has no effect on the Aβ-producing enzymes β- and γ-secretases [58].
2.1.2. Targeting Amyloid Clearance
According to the amyloid cascade hypothesis, one of the reasons for Aβo accumulation in
the brain is related to the impairment of the clearance mechanisms (Figure 2). These pathways
can therefore be targeted as potential preventive/treatments strategies for AD. The neuroprotective
mechanism, however, remain unclear with only the activation of AMP-activated protein kinase
(AMPK) signaling being proposed as one of the signaling pathways. For example, resveratrol activates
AMPK by increasing cytosolic Ca2+ levels and by promoting Ca2+/ Ca2+-calmodulin-dependent
protein kinase kinase-β (CaMKKβ) dependent phosphorylation of AMPK. Furthermore, resveratrol
reduces Aβ accumulation by activating autophagy and by facilitating the lysosomal degradation
of Aβ (Figure 4) [59]. Insulin-like growth factor-I (IGF-I) stimulates β-amyloid release from
neurons and promotes brain amyloid clearance (Figure 4) [60]. Resveratrol (20 mg/L) increases
hippocampal IGF-I production, thereby improving cognitive function in mice, probably due to
an increase in amyloid clearance [61]. Resveratrol (0–20 µM) also induces autophagy in PC12
cells, a process partially mediated through the activation of the tyrosyl transferRNA (tRNA)
synthetase (TyrRS)-auto-poly-ADP-ribosylation of poly (ADP-ribose) polymerase 1 (PARP1)-SIRT1
signaling pathway [62]. The flavanol quercetin (20–40 kg/kg) also increases AMPK activity in the
APPswe/PS1dE9 transgenic mouse model of AD and, therefore, promotes the clearance of intracellular
Aβ (Figure 4) [63].
Increasing the levels of degrading enzymes has been studied as a therapeutic possibility.
Resveratrol (0–40 µM) promotes the intracellular degradation of Aβ in cell lines by a mechanism that
implicates the proteasome [58]. In an in vivo AD model of Caenorhabditis elegans resveratrol (100 µM)
increases the degradation of aged proteins by autophagosomal and proteasomal degradation [64].
Diet supplementation with resveratrol (1 g/kg) promotes an increase in neprilysin levels, one of the
most important amyloid-degrading enzymes, in both 3xTg-AD and healthy wild type mice. In this
study, and for the first time in vivo, it was also shown that resveratrol promotes enhancement of
ubiquitin-proteasome system (UPS), which leads to a reduction of aberrant amyloid and tau proteins.
Taken together these results show that resveratrol has a potential in AD prevention by increasing brain
resilience against aberrant proteins (Figure 4) [33].
2.1.3. Targeting Amyloid Aggregation
AD is characterised by aggregation of Aβ monomer into multimeric aggregates (Figure 2).
Resveratrol has direct effects in Aβ aggregation, both by preventing conversion of lower to higher
molecular weight oligomers [65] but also by disrupting Aβ aggregates (Figure 4) [66]. Resveratrol
and its glucoside are specific potent inhibitors of Aβ aggregation [67]. Resveratrol inhibits
Aβ42 fibril formation in a dose-dependent way but could not prevent Aβ42 oligomerization [68].
Inhibition of Aβ42 fibril formation could be explained by ability of resveratrol to directly bind to
monomer and fibril Aβ, as determined by surface plasmon resonance, thioflavin T fluorometric
analysis, proton nuclear magnetic resonance, and atomic force microscopy in vitro [69]. The result
is the conversion of soluble oligomers, fibrillar intermediates and amyloid fibrils to non-toxic
high molecular weight conformation [70]. Moreover, resveratrol can indirectly prevent Aβ
aggregation, through improvement of the binding of transthyretin to Aβ oligomers (Figure 4) [71].
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In addition to resveratrol, a naturally derived grape seed polyphenolic extract (200 mg/kg/d)
inhibits amyloid β-protein aggregation into high-molecular-weight oligomers in vitro. When
orally administered to Tg2576 mice, this polyphenolic preparation attenuates AD-type cognitive
deterioration coincidentally with reduced high-molecular-weight soluble oligomeric Aβ in the
brain [72]. Furthermore, experiments carried out with quercetin (200 µM) show a potent Aβ42
anti-aggregation activity (75.4%) in combined in vitro cell-based/in silico assay approaches [73].
Such data were further confirmed where treatment with quercetin (25 mg/kg) for three months
decreased β-amyloidosis in aged 3xTg-AD mice [74]. Furthermore, polyphenolic metabolites identified
in the rat brain are after oral dosage of Cabernet Sauvignon red wine were tested for potential
AD benefits. It was observed that quercetin-3-O-glucuronide (0–5 µM) reduces the generation of
Aβ peptides by primary neuron cultures generated from the Tg2576 AD mouse model. Another
brain-targeted metabolite, malvidin-3-O-glucoside (0–50 µM), has no detectable effect on Aβ generation.
Quercetin-3-O-glucuronide also interferes with the initial protein-protein interaction of Aβ1–40 and
Aβ1–42, which is necessary for the formation of neurotoxic oligomeric Aβ species (Figure 4) [75].
Finally, a preclinical study demonstrated that grape seed proanthocyanidin (GSPA), which consists
of catechin, epicatechin and epicatechin gallate, can interrupt the aggregation of neurotoxic Aβ
(Figure 4) [76]. Altogether these data suggest that polyphenols may have the potential to reduce
protein aggregation, a phenomenon important in AD progression.
2.2. Targeting Tau Protein
Neuroprotective effects of resveratrol also result from the inhibition of tau protein
hyperphosphorylation, as it was observed in N2a cells exposed to formaldehyde. Inhibition of glycogen
synthase kinase (GSK-3β) and calmodulin-dependent protein kinase II (CaMKII) or the activation of
protein phosphatase-2A (PP2A) by resveratrol (2.5–50 µM) protect against the hyperphosphorylation
and/or mediates the dephosphorylation of tau protein, respectively (Figure 4) [77]. Resveratrol
also inhibits Na3VO4-induced hyperphosphorylation of tau at the Ser396 (p-S396-tau) site, which is
upregulated in the hippocampus of AD brains and predominantly linked to AD-associated cognitive
dysfunction [78].
Recently, the inhibitory effect of quercetin on okadaic acid (OA)-induced tau protein
hyperphosphorylation in HT22 cells was also explored. Western blotting results indicated that
quercetin attenuates OA-induced tau protein hyperphosphorylation at the Ser396, Ser199, Thr231
and Thr205 sites. Quercetin also inhibits the activity of cyclin-dependent kinase 5 (CDK5), a key
enzyme in the regulation of tau protein, and blocks the Ca2+-calpain-p25-CDK5 signaling pathway.
These observations indicate the ability of quercetin to decrease tau protein hyperphosphorylation and
thereby to attenuate the associated neuropathology (Figure 4) [79]. Anthocyanins were reported to
activate the phosphorylation of anti-phosphorylated GSK3β at Ser 9, thereby possibly preventing
GSK-3β-dependent tau hyperphosphorylation at Ser 413 and 404 [80]. GSPA is also able to decrease
hyperphosphorylated tau deposition in APP/PS1 male heterozygous mice (Figure 4) [76].
In addition to flavonoids, the hydroxycinnamate caffeic acid (10–20 µg/mL) was reported
to protect PC12 cells against Aβ-induced toxicity by decreasing tau phosphorylation through the
reduction of GSK-3β activation [81].
2.3. Targeting Oxidative Stress
Resveratrol protects the nervous tissue by reducing ROS production and by affecting several
mechanistic pathways. For example, resveratrol reduces OS in the brain by preventing nuclear
factor-κB (NF-κB) activation (Figure 4) [82]. AMPK is a key protein in the regulation of cell survival
in response to OS insults and resveratrol is a potent AMPK-activator, as shown in Neuro2a cells
and primary neuronal in vitro as well as in the brain [83]. Resveratrol also activates SIRT1 in
the hippocampus [84], neuronal cells [85], rat cortical primary neurons [86] and thus reduces OS.
Different results were observed by Karuppagounder et al. (2009), and they suggested that dietary
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supplementation with resveratrol protects against Aβ plaque formation and OS without activation of
SIRT1 [87]. Resveratrol reduces both lipid peroxidation levels and OS induced by Aβ senile plaques
in hippocampal neuronal cells (Figure 4) [88]. Inducible nitric oxide synthase (iNOS) mediates the
Aβ-induced lipid peroxidation and HO-1 (heme oxygenase 1) expression, and resveratrol protects
adult male rats from Aβ-induced neurotoxicity through the downregulation of iNOS (Figure 4) [89].
Induction of HO-1 by resveratrol is also observed in a dose- and time-dependent manner in cultured
mouse cortical neuronal cells, revealing that resveratrol provides neuroprotection from free-radical
or excitotoxicity damage [90]. Resveratrol also restores intracellular antioxidant enzymes such
as GSH levels in a cell culture model [91,92] or reverses Aβ-induced malondialdehyde (MDA)
overproduction derived from the lipid membrane oxidation, which reflect the overall degree of
free radical attack (Figure 4) [89]. Resveratrol shows antioxidant proprieties, which may contribute to
ameliorate the cognitive deficits and to attenuate oxidative damage in the brain of the SAMP8 mice
through scavenging free radicals and modulating activities of antioxidant enzymes (Figure 4) [93].
As aforementioned resveratrol downregulates GSK-3β, a protein that induces OS [91]. Not only
resveratrol but also the flavonoids quercetin and (+)-catechin protect hippocampal cells against toxicity
induced by nitric oxide (NO). Quercetin can block sodium nitroprusside-stimulated protein kinase C
(PKC) activation, pointing to a possible involvement of this enzyme in the protective effects mediated by
quercetin (Figure 4) [94]. Recently, effects of solid lipid nanoparticle of quercetin in pentylenetetrazole
(PTZ) induced cognitive impairment of Danio rerio species were evaluated. The administration of
quercetin nanoparticles (5 and 10 mg/kg) ameliorate the PTZ exposure induces cognitive impairment,
due to its potential anti-oxidative, anti-lipid peroxidative and acetylcholinesterase (AChE) inhibitory
actions [95]. Epicatechin and myricetin, could inhibit neuronal death, through antioxidative
mechanisms in cultured mouse cortical neurons (Figure 4) [96]. Anthocyanins (200 mg/kg) also
attenuate memory deficits, protects against oxidative damage in the brain, and restore AChE and
ion pump activity in a rat experimental model of sporadic dementia of Alzheimer’s (Figure 4) [97].
Finally, caffeic acid protects PC12 cells against Aβ-induced toxicity through the inhibition of OS and
the inhibition of intracellular Ca2+ levels [81].
3. Parkinson Disease (PD)
Parkinson disease is the second most common neurodegenerative dementia and the most common
neurodegenerative movement disorder. It can be inherited, but most of the cases are sporadic, still both
have selective loss of dopaminergic neurons in the substantia nigra that project to the basal ganglia.
It is characterized by bradykinesia, tremor, rigidity and postural instability triggered by dopamine
decrease [98]. Other regions of the central and peripheral nervous system could be involved and
contribute to a range of non-motor symptoms like autonomic dysfunction, depression, and cognitive
deficits [99]. Most of the PD cases show Lewy pathology consisting of Lewy bodies and Lewy neurites
revealed by histological techniques. α-Synuclein (α-syn) is the major component of the Lewy body
(Figure 5) [100]. Natural forms of α-syn protein are the monomeric and possibly tetrameric α-syn
ones, which have a physiologic function. They regulate exocytosis and promote microtubule formation
through interactions with tubulin. In PD, α-syn changes from its monomer arrangement to protofibrils,
fibrils and oligomers, which are involved in toxic processes, protofibril and fibril structures, being
probably the most toxic ones. Their production, truncation and maintenance are fundamental to PD
pathology (Figure 5). Toxic effects of α-syn include mitochondrial dysfunction, endoplasmic reticulum
(ER) stress, impaired proteostasis, enhanced neuroinflammation and pathological aggregation of
other proteins [101]. Protein misfolding and aggregation, mitochondrial dysfunction, cell cycle
reactivation, apoptosis and excitotoxicity contribute to OS occurrence in PD (Figure 5) [102]. Another
oxidative scenario arises when the dopamine is degraded to eliminate cytosolic excess of this
neurotransmitter after treatment. Dopamine is easily metabolized via the monoamine oxidase (MAO)
or by auto-oxidation. MAO is in outer mitochondrial membrane in neuronal and glial cells and is able
of degrade dopamine, which exacerbates degeneration of dopaminergic neurons. 6-Hydroxydopamine
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(6-OHDA) and H2O2 are products of dopamine degradation by MAO, and contribute to an increase in
ROS production and OS damage [103].Beverages 2018, 4, x FOR PEER REVIEW    11  of  23 
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As in other neurodegenerative diseases, the mitochondrion plays a role in PD pathogenesis.
Mitochondria are the primary source of ROS that may contribute to intracellular OS. The main sites
of ROS production in mitochondria are complex I and to a smaller extent complex III in the ETC.
The foremost process for ROS production in PD is complex I deficiencies, which is responsible for
the majority of unfavorable neural apoptosis generation [104]. Briefly, ETC complex I deficiency,
leads to ROS production, reducing levels of the GSH, which induces mitochondrial permeability by
transiently opening a pore. Subsequently occurs the depolarization of the mitochondrial membrane
potential (Figure 5). These events ultimately lead to neural cell death via the release of pro-apoptotic
mitochondrial proteins, including cytochrome c and apoptosis-initiating factor [105].
Neuroinflammation is a characteristic of PD pathology, but it remains unknown whether
neuroinflammation promotes or protects from neurodegeneration. Under pathological conditions,
such as protein aggregation, gene mutations, environmental factors and cytokines released from
infiltrated T cells and microglia become activated and release pro-inflammatory mediators. The latter
activate astrocytes, leading to elevated production of proinflammatory factors, NO, O2 −, contributing
to degeneration of dopaminergic neurons (Figure 5). Degenerative neurons release molecules that
can activate glia and increase inflammatory response. At certain stage of PD, a different microglia
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subpopulation may become active releasing anti-inflammatory factors, including transforming growth
factor beta (TGF-β), and exert a neuroprotective effect in PD (Figure 5) [106].
3.1. Targeting Dopaminergic Neurons Cytotoxicity
Pre-treating SH-SY5Y human neuroblastoma cells [107] and 6-OHDA rat models of PD with
resveratrol (20 mg/kg) results in inhibition of dopamine cytotoxicity [108]. Resveratrol reduces
intracellular OS in neurotypical SH-SY5Y, through recognized signal pathways of apoptosis. In fact,
resveratrol pre-treatment led to a decrease in cleavage of PARP, an increase in the Bcl-2 protein,
and activation of caspase-3 [107]. Rotenone is a popular pesticide that could produce 1-methyl-
4-phenylpyridine (MPP+) and, consequently, can cause apoptosis in dopaminergic neurons [109].
Resveratrol shows concentration-dependent neuroprotective effects against sodium azide and
thrombin, a mitochondrial complex IV inhibitor and a microglia-activating agent, respectively.
Moreover, SIRT inhibitors such as nicotinamide and sirtinol, do not attenuate the protective effect
of resveratrol against MPP+ cytotoxicity [110]. Resveratrol also alleviates MPP+-induce cytotoxicity
and restored MPP+-induced mitochondrial dysfunction in SN4741 cells. These results suggest that
resveratrol attenuates MPP+-induced mitochondrial dysfunction and cell apoptosis, which may be
achieved through AKT/GSK-3β pathway [111].
Resveratrol (0–50 µM) also protects PC12 cells from 6-OHDA-induced OS and apoptosis via
C-X-C chemokine receptor type 4 (CXCR4) signaling pathway [112]. CXCR4 is a common and
highly conserved G-protein-coupled receptor (GPCR) with seven transmembrane domains and is a
receptor for receptor for CXCL12 that can promote neuronal apoptosis [113]. CXCL12/CXCR4 may be
involved in PD occurrence and could be a molecular target for PD [114]. Resveratrol (20 µM) protects
SH-SY5Y cells against rotenone-induced neuronal apoptosis, inducing HO-1 expression and preventing
dopaminergic cell death by regulating autophagic flux [115]. N-methyl-N′-nitro-N-nitrosoguanidine
(MNNG) is a DNA alkylating agent that causes neurotoxicity. Resveratrol (0–100 µM) suppresses
MNNG-induced increase in acetylation of p53, a representative target of SIRT deacetylase activity,
in midbrain slice culture [110]. Resveratrol (50 µM) inhibits 6-OHDA-induced toxicity and increased
the expression of SIRT1 in PC12 cells [116]. Recently, it was observed that resveratrol (0–50 µM)
reduces rotenone induced neuronal damage in PC12 cells, and it was suggested that SIRT1/Akt1
(Akt1, serine/threonine-protein kinase) signaling pathway play an essential role in this process [117].
Resveratrol (20 mg/Kg) also activates PGC-1α in dopaminergic cells via the deacetylase SIRT1, and
enhanced PGC-1α gene transcription with increases in superoxide dismutase 2 (SOD2) and Trx2
in the MPTP mouse model of Parkinson’s disease [118]. Ferretta et al. (2014) tested in vitro the
effect of resveratrol treatment on primary fibroblast cultures from two patients with early-onset
PD linked to different Park2 mutations. The authors suggested SIRT1/AMPK/PGC1-α axis as a
key neuroprotective pathway [119]. On PD cellular models, resveratrol has neuroprotective effects
mediated through activation of the AMPK-SIRT1-autophagy pathway [120]. As suggested by in vitro
evidences, activation of SIRT1 could explain the improvement both the motor deficits and pathological
changes of PD in mice. It was suggested that activation of SIRT1, led to LC3 deacetylation mediated
autophagic degradation of α-syn [121]. In a different in vivo study, resveratrol improved rat’s
movement and spatial memory performance by rescuing the reduction of SIRT1 expression and
CREB phosphorylation induced by Aβ1-42 [114]. Together, these results indicate that neuroprotective
actions of resveratrol against different type of insults is related to SIRT-activating potential.
Quercetin can successfully activate PKD1, the gene that encodes the polycystin 1 protein,
pro-survival signaling in dopaminergic cells. Quercetin also induces Akt and CREB phosphorylation
and brain-derived neurotrophic factor BDNF expression. Therefore, PKD1/CREB/BDNF axis may
at least partially mediate the neuroprotective effects of quercetin. Quercetin treatment increases
mitochondrial biogenesis in dopaminergic neurons. Importantly, quercetin protects against dopaminergic
neurodegeneration in the MitoPark transgenic mouse model of PD, an animal model of PD with impaired
respiratory chain function in dopaminergic neurons [122]. Quercetin binds covalently with α-syn in 1
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to 1 ratio. The formed quercetin-α-syn adducts attach to the α-syn oligomers or monomers, increasing
the surface hydrophilicity and inhibiting the further fibrillation [123]. Also, caffeic acid proved to be an
efficient inhibitor against α-syn fibrillation [124]. Gallic acid inhibits α-syn fibrillation and toxicity by
stabilizing the non-toxic oligomeric structure of α-syn through oligomer binding [125].
Pure polyphenols such as gallic acid, ferulic acid, caffeic acid, coumaric acid, propyl gallate,
epicatechin, epigallocatechin, and epigallocatechin gallate protect, rescue and, most importantly,
restore the impaired movement activity (i.e., climbing capability) induced by paraquat in Drosophila
melanogaster, a valid model of PD [126]. Interestingly, ferulic acid and exercise seem to improve
the motor performance in a PD rodent model which might be due to the upregulation of Hsp70 and
increasing density of dopaminergic neurons in the corpus striatum. Ferulic acid offers more protective
effects than exercise and combination of both did not offer more protection than ferulic acid alone [127].
3.2. Targeting Oxidative Stress
As previously mentioned, resveratrol is a very promising antioxidant, therefore several
in vitro and in vivo experiments have been carried out to evaluate its potential to ameliorate PD.
In neuronal-like cells expressing mutant huntingtin from dopamine toxicity, resveratrol (100 µM)
prevents the generation of ROS and restores the level of ATG4, a redox-sensitive autophagy protein
that plays a pivotal role in autophagosome formation [128]. Resveratrol also prevents the decrease of
dopaminergic neurons and the increase of propidium iodide uptake into midbrain slices induced by an
MPP+. In addition, resveratrol was reported to block the accumulation of ROS, the depletion of cellular
GSH, and the cellular oxidative damage induced by MPP+, suggesting the involvement of antioxidative
properties in the neuroprotective action of this stilbene [110]. A botanical extract (Regrapex-R®,
Interpharma Praha, a.s, Modrany, Czech Republic) prepared from whole grape (Vitis vinifera) and
Polygonum cuspidatum, which contains polyphenols, including flavans, anthocyanins, emodin, and
resveratrol, exhibit dose-dependent scavenging effects on ROS. Extract inhibits ROS and protein
carbonyl production and protects enzyme activities of ETC (complexes I and II) and pyruvate
dehydrogenase in isolated rat liver mitochondria following exposure to 2,2′-azobis (2-amidino propane)
dihydrocholoride (AAPH), a potent lipid oxidant generator. The polyphenolic mixture also protects
human neuroblastoma cells (SKN-MC) against AAPH induced oxidation by maintaining cell viability
and inhibiting excessive ROS generation. In transgenic Drosophila expressing human α-syn, model
for PD, the botanical extract improves climbing ability and extends females lifespan [129].
Resveratrol (20 mg/Kg) ameliorates 6-OHDA-induced rat brain injury [108], upregulating the
antioxidant status [108], and suppressing overexpression’s of cyclooxygenase-2 (COX-2), TNF-α
mRNA and protein in the substantia nigra [130]. Resveratrol also mediates anti-inflammatory
activities by suppressing the activity of NADPH oxidase and, further, decreasing ROS production
and inhibiting the activation of mitogen activated protein kinases (MAPKs) and NF-κB cascade
signaling pathways, as it was shown in lipopolysaccharide (LPS)-induced dopamine neurons [131].
Resveratrol shows potential therapeutic capacity for rotenone-induced PD in rats through inhibiting
endoplasmic reticulum stress-mediated apoptosis. Resveratrol also restores redox balance as evident
by suppressing xanthine oxidase activity and protein carbonyls formation; in addition to preservation
of intracellular antioxidants status via activating glutathione peroxidase (GPx) and Nrf2 signaling
pathway [132]. Resveratrol has neuroprotective effects, through free radical scavenging, in animals in
which PD is induced with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [133–135]. Resveratrol
administration protects mice from MPTP-induced motor coordination impairment, hydroxyl radical
overloading, and neuronal loss [134]. Reverses in toxic effects of MPTP were posteriorly confirmed
in study with mice, intraperitoneal injected with MPTP (50 mg/kg body weight). It was observed
that, resveratrol increases the levels of dopamine, its metabolites, GSH and GPx activities and reduces
levels of thiobarbituric acid reactive substances (TBARS), catalase and SOD activities and enhances
behavior performance [135].
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Quercetin has a dual effect against the 6-OHDA-induced ROS formation in catecholaminergic
SH-SY5Y neuroblastoma cells. Small concentrations of quercetin gave some protection, but at high
concentrations this protective effect is reduced, or even enhanced toxicity occur [136]. The dual effect
of quercetin was observed in other studies using the same [137] and a different in vitro model [138].
Quercetin protection and toxicity effects can be described in a time-based manner. At earlier exposure
times, quercetin has strong protection against 6-OHDA-induced cell death in SH-SY5Y cells. In contrast,
after a prolonged treatment quercetin do not protect against 6-OHDA toxicity [137]. Also, both
quercetin aglycone and quercetin 3-O-β-d-glucuronide suppress the production of H2O2 by scavenging
O2•– derived from 6-OHDA in a neuro-2a cell culture system. According with this conjugated quercetin
metabolites could scavenge ROS generated from dopamine metabolism, however, their deconjugation
to quercetin aglycone is essential to exert protective effects against the neuronal cell death induced
by ROS. Re-conjugation is also needed to avoid the inherent cytotoxicity of quercetin aglycone [139].
Moreover, quercetin protects SH-SY5Y cells in which neurotoxicity was induced by lipopolysaccharide
plus interferon-γ or interferon-γ released from activated microglia and astrocytes. Quercetin can reduce
oxidative/nitrative damage to DNA as well as to the lipids, and proteins of SH-SY5Y cells. Quercetin
also increases GSH concentration in SH-SY5Y cells [140]. In a study carried out by Ahn and Jeon (2015),
quercetin pre-treatment increased α-syn expression in PC12 cells treated with various toxins. Knocking
out α-syn, however, exerted no significant effect on cell survival. This could mean that quercetin is
neuroprotective against toxic agents via affecting various mechanisms such as apoptosis, autophagy
and aggresome [141].
Regarding quercetin, inconsistent results were observed in vivo, some studies suggest that
quercetin has no neuroprotective effect in vivo using 6-OHDA rat models of PD [136,142], while others
suggest that quercetin protects striatal dopaminergic neurons against 6-OHDA-induced OS in the
rat [143]. Pre-treatment with quercetin has no effects on the number of hydroxylase (TH)-positive cells
in the substantia nigra and on dopamine content in the striata [142]. Results from an in vitro and in vivo
study revealed a dose-dependency of quercetin effect. Quercetin displays a clear falling of protection at
higher concentrations in both viability and caspase-3 like activity in cell cultures and to some extent also
in circling behavior in lesioned rats. This dose-dependency of quercetin effect occurs in a thinner range
of concentrations, since cytotoxic effects of quercetin begin to take place at concentration only twofold
higher than the one that provides the greatest protection [137]. In a posterior study, it was described
that quercetin mitigates the loss of complex-I activity induced by rotenone in rats and enhances
antioxidant enzyme activity [144]. Using the same animal model of PD, El-Horany et al. (2016) showed
that quercetin attenuates rotenone-induced behavioral impairment, increases autophagy, ameliorates
endoplasmic reticulum stress-induced apoptosis with attenuated OS [145]. From the current study,
quercetin can act as an autophagy enhancer in PD rat model and modulates the microenvironment
that leads to neuronal death. Combined strategies could be a better approach as suggested by
Haleagrahara et al. (2013) after evaluating the combined treatment with quercetin and desferrioxamine
on 6-OHDA-induced neurotoxicity in the striatum of rats. They observed that combined treatment
has a more powerful effect in protecting the neurons and increasing the antioxidant enzymes in
the striatum [146]. The combination of quercetin with other neuroprotector compounds have been
suggested as a therapeutic advantage in the prevention/treatment of OS-mediated neurodegenerative
conditions such as PD [147–149].
Organic and aqueous Champagne wine extracts exhibit potent neuroprotective activity against
peroxynitrite-induced injury at low concentrations (0.1 µg/mL). Results suggest that neuroprotective
effect against oxidative neuronal injury is in part due to the cellular actions of individual components
found in the organic extracts, particularly tyrosol, caffeic acid, and gallic acid [150]. Neuroprotective
effects of tyrosol, caffeic acid, gallic acid, p-coumaric acid, (+)-catechin, (−)-epicatechin and quercetin
(0.1–50 µM) and organic champagne extract against CysDA-induced neuronal injury were evaluated
in posterior studies, that showed that hydroxycinnamates, phenolic acids and phenolic alcohols
induce neuroprotective effects, which are more powerful than that observed for flavonoids [138,151].
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Gallic acid has neuroprotective activity against 6-OHDA-induced OS via enhancement of cerebral
antioxidant defense, by increasing total thiol and GPx contents and decreasing MDA levels in the
rat hippocampus and striatum tissues [152]. Catechin treatment restores GSH levels, and increases
dopamine and 3,4-dihydroxyphenylacetic acid content, and tyrosine hydroxylase -immunoreactivity
in 6-OHDA-lesioned rats [153]. Kaempferol also shows neuroprotective effects in MPTP-induced PD
mice, by scavenging ROS, which results in the survival of more dopamine neurons [154].
4. Conclusions
Epidemiological studies suggest that moderate consumption of wine, an element of the
Mediterranean diet, is one of the main factors behind the neuroprotective effects observed in some
populations [7,155–158]. Most of the in vivo and in vitro studies evaluated wine neuroprotection
indirectly by analyzing effects of the phenolic compounds of wine, mainly resveratrol. Nonetheless,
much of the data obtained on their bioactivity derived from short term basis in vitro or in vivo studies
where the dose used were not of nutritional relevance and unlikely achievable through moderate
wine drinking. Although at the moment, the balance of evidence does suggest that polyphenol effects
contribute to the benefits of a high intake of fruits and vegetables, the extent of their contribution
in vivo and at physiological relevant concentrations remains uncertain. More work needs to be done to
prove whether this class of compounds is most likely to result in health benefits and to determine their
beneficial effects in slowly developing neurodegenerative disorders. These studies remain however
fundamental to understand the effects of those compounds in the brain; to highlight that wine is a
complex chemical mixture. Analysis of the literature led us to hypothesize that preventive/therapeutic
efficacy of wine is more likely due to a combination of neuroprotective effects of wine phenolic
compounds. Combined complementary and perhaps synergistic effects could explain the benefits of
wine moderate consumption. In fact, the hypothesis that wine could be compared to combined and
multi-target therapeutic strategies could explain that drinking lower doses on a “chronic” manner
reduces brain damage. It is also very important to continue studying the effects of phenolic metabolites,
however, a focus on gut microbiota derived phenolic acids and other metabolites should be addressed.
Differences observed among populations in epidemiologic studies could be, in our opinion, attributed
to differences in the gut microbiota composition since they are affected by diet. The type and quantity
of metabolites produced after a meal will differ according with gut microbiota. In conclusion, wine is a
complex mixture which is effective to prevent or slow age-related neurodegenerative diseases because
can modulate multiple targets simultaneously involved in these diseases.
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